Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care - 11/09/11
The Coumadin Aspirin Reinfarction (CARS) Pilot Study Groupab
Abstract |
In conclusion, the central laboratory provides INR results in close agreement with the local laboratory for monitoring the anticoagulant effect of low-dose warfarin. The findings suggest further evaluation of the central laboratory to monitor adjusted warfarin therapy at currently recommended therapeutic ranges.13 The cost-effectiveness of using a central laboratory should also be evaluated.
Le texte complet de cet article est disponible en PDF.| This study was supported by grants from the National Institute of Health (HL-30443) and a National Institutes of Health Institutional Development Award (IdeA); by Applied Research Grant AR2–051 from the Oklahoma Center for the Advancement of Science and Technology; and by a grant from the Du Pont Merck Pharmaceutical Company. This work was performed during the tenure of a fellowship from the Presbyterian Health Foundation (S.S.D.), and was supported by National Research Service Award HL 08756-02 from the National Heart, Lung, and Blood Institute. |
Vol 78 - N° 9
P. 1074-1076 - novembre 1996 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
